Table 2.
MET targeted therapies
| Strategy | Molecules | Developmental stage |
| Silence MET RNA | Small interference RNA | In vitro success |
| Paxillin specific siRNA | In vitro success | |
| microRNA | In vivo success | |
| Inhibit HSP90 (chaperone protein) | Geldanamycin | Phase 2 clinical trials underway |
| Compete with HGF | Pro-HGF | In vivo success |
| NK2 | Failed in vivo study | |
| NK4 | In vivo success | |
| Bind HGF before it activates MET | Decoy MET receptor | In vivo success |
| Anti-HGF antibodies | Phase 2 clinical trials | |
| Broad spectrum (Non-specific) kinase inhibitors | K252a | In vivo success |
| RPI-1 | In vivo success | |
| Narrow spectrum (MET specific) kinase inhibitors | SU11274 | In vitro success |
| PHA665752 | In vitro success | |
| PF2341066 | In vivo success | |
| XL 880 | Phase 2 clinical trials | |
| XL184 | Phase 3 clinical trials | |
| ARQ197 | Phase 2 clinical trials | |
| SGX523 | Stopped in Phase 1 trials | |
| MGCD265 | Phase 2 clinical trials |